August 2012- Volume 8, Issue 8

August 2012

In this Issue

Contract Services

Global peptide partnership

Global peptide partnership

Peptisyntha and Peptides International will collaborate to produce research-grade peptide active pharmaceutical ingredients

Control issues

Control issues

Bend Research and Catalent partner to provide integrated solutions for oral controlled-release technologies

Renaissance Pharma acquires DPT, a CDMO

Renaissance Pharma acquires DPT, a CDMO

Pharma drawn to DPT’s contract development and manufacturing capabilities

Solving the insoluble

Solving the insoluble

Quotient Clinical and Capsugel will collaborate to accelerate early development and clinical evaluation for poorly soluble drugs

Research & Development

Collaboration targets complications

Collaboration targets complications

Sanofi, Joslin Diabetes Center to develop new medicines to treat diabetes and related disorders

CoMMpass to multiple myeloma treatment

CoMMpass to multiple myeloma treatment

MMRF and US Oncology Research collaborate on landmark clinical study to advance personalized treatments for incurable blood cancer

A cognitive collaboration

A cognitive collaboration

Roche, Seaside Therapeutics form alliance to discover, develop new drugs for fragile X syndrome, autism spectrum disorders

A bioscaffold for heart disease repair

A bioscaffold for heart disease repair

ADAPT technology could augment tissue repair in heart

Surprising and sizable injection

Surprising and sizable injection

BMS-AstraZeneca diabetes partnership gets $7- billion boost with BMS’ acquisition of Amylin Pharmaceuticals

Global News

MCPs for COPD and asthma

MCPs for COPD and asthma

Prosonix and the Imperial College London partner on engineered multi-component particles for respiratory medicines

GSK finalizes Human Genome Sciences acquisition for $14.25 per share in cash

GSK finalizes Human Genome Sciences acquisition for $14.25 per share in cash

The transaction values HGS at approximately $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt

An acquisition with some heart

An acquisition with some heart

Janssen-Cilag acquires CorImmun, gains heart failure drug

Of warheads and wellness

Of warheads and wellness

Cancer Research Technology and ADC Therapeutics join forces on antibody-drug conjugates

Tackling the TB epidemic

Tackling the TB epidemic

AstraZeneca, Cellworks and Wellcome Trust team up to fight drug-resistant tuberculosis

Valeant all smiles over OraPharma

Valeant all smiles over OraPharma

Valeant acquires oral health company for $312 million

Omics & Systems Biology

Discovery on demand

Discovery on demand

Merck Serono, Compugen launch company to develop predictive drug toxicity tests

Zebrafish turn the tide in autism research

Zebrafish turn the tide in autism research

MIT researchers turn to fish models to uncover secrets of autism

Hit-to-lead

Hit-to-lead

CellCentric and ZoBio enter into partnership to develop lead compounds against epigenetic drug targets

Hiding in plain sight

Hiding in plain sight

Researchers working on both sides of the Atlantic describe new influenza gene hidden among the known ones

Diagnostics

Custom-tailored therapy

Custom-tailored therapy

Merrimack and Cancer Treatment Centers of America partner to advance translational research and individualized treatment

Breaking the Parkinson’s bottleneck

Breaking the Parkinson’s bottleneck

Berg Pharma partners with Parkinson’s Institute to identify biomarkers in Parkinson’s disease

Lilly, PrimeraDx break the ICE

Lilly, PrimeraDx break the ICE

Companies team up to develop companion diagnostics using PrimeraDx’s ICEPlex platform

Tools & Technology

Tegal acquires CollabRx

Tegal acquires CollabRx

Deal brings interpretive content and data analytics to genomics-based medicine

Eyes on the Ion

Eyes on the Ion

Life Technologies and Boston Children's Hospital to develop optimized lab workflow based on Ion Proton Sequencer

Stepping up to the platform

Stepping up to the platform

NCKU, Fujitsu ink MOU to build genomics platform

KREATECH Diagnostics, ORIDIS Biomarkers go FISH

KREATECH Diagnostics, ORIDIS Biomarkers go FISH

Companies to develop state-of-the-art REPEAT-FREE DNA-FISH assays for the oncology field

QIAGEN to create NGS portfolio for clinical research, MDx

QIAGEN to create NGS portfolio for clinical research, MDx

QIAGEN NV recently unveiled an initiative to enter the field of next-generation sequencing (NGS)

The life science DREAM team

The life science DREAM team

Seventh-annual Dialogue for Reverse Engineering Assessment and Methods (DREAM) challenge seeks informatics solutions to support translational medicine

Editor's Focus

Public misconceptions about stem cells throw a wrinkle into scientific progress

Public misconceptions about stem cells throw a wrinkle into scientific progress

The great divide between actual science and general public perception—complicated by political controversy and ethical debate—has only grown deeper with every breakthrough or achievement in the quest to use stem cells to regenerate or repair damaged tissue, skin and organs.

Commentary

August is back-to-school month

August is back-to-school month

We’ve followed the science education debate for years, but jumping into the fray has caused us to think in new ways.

The promise of cell therapies in treating chronic diseases

The promise of cell therapies in treating chronic diseases

With the introduction of adult stem cell therapies, we are now seeing new promise in the management and even treatment of chronic disease.

Special Reports

SPECIAL REPORT: Regenerating interest in stem cell medicine (PART 2)

SPECIAL REPORT: Regenerating interest in stem cell medicine (PART 2)

Stem cell technologies still hold potential to replace organs and tissues, but initial hype has been toned down

SPECIAL REPORT: Regenerating interest in stem cell medicine (PART 1)

SPECIAL REPORT: Regenerating interest in stem cell medicine (PART 1)

Stem cell technologies still hold potential to replace organs and tissues, but initial hype has been toned down
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Drug Discovery News November 2024 Issue

Latest Issue  

• Volume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue